HiJAKing the epigenome in leukemia and lymphoma
Authors:
- 12 April 2017
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (11) , 2540-2547
Abstract
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by receptors of diverse cytokines, growth factors, and other related molecules. Many of these receptors transmit anti-apoptosis, proliferation, and differentiation signals that are critical for normal hematopoiesis and immune response. However, the JAK/STAT signaling pathway is deregulated in many hematologic malignancies, and as such is co-opted by malignant cells to promote their survival and proliferation. It has recently come to light that an alternative mechanism, wherein nuclear JAKs epigenetically modify the chromatin to increase gene expression independent of STATs, also plays an important role in the pathogenesis of many hematologic malignancies. In this review, we will focus on common genetic alterations of the JAK family members in leukemia and lymphoma, and provide examples in which JAKs regulate gene expression by targeting the cancer epigenome.Keywords
Funding Information
- National Cancer Institute (1R01 CA187299)
- UW-Madison T32 Hematology Training Award (T32 HL07899)
This publication has 66 references indexed in Scilit:
- Three Distinct Patterns of Histone H3Y41 Phosphorylation Mark Active GenesCell Reports, 2012
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphomaBlood Cancer Journal, 2011
- LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell diseaseNature Cell Biology, 2010
- Cooperative Epigenetic Modulation by Cancer Amplicon GenesCancer Cell, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid TumorsCancer Cell, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- JAK signaling globally counteracts heterochromatic gene silencingNature Genetics, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005